IFM (Intergroupe francophone du myélome) recommendations for uniform interpretation of serum and urine protein electrophoresis in multiple myeloma diagnosis and follow-up.
Dejoie T et al. Ann Biol Clin (Paris). 2016 Aug 1;74(4):429-441.

Application of PET/CT in treatment response evaluation and recurrence prediction in patients with newly-diagnosed multiple myeloma.
Li Y et al. Oncotarget. 2016 Aug 19. doi: 10.18632/oncotarget.11418. [Epub ahead of print].

The independent association of mean platelet volume with overall survival in multiple myeloma.
Zhuang Q et al. Oncotarget. 2016 Aug 23. doi: 10.18632/oncotarget.11551. [Epub ahead of print].

Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma.
Huang SY et al. Oncotarget. 2016 Aug 23. doi: 10.18632/oncotarget.11519. [Epub ahead of print].

Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry.
Mills JR et al. Clin Chem. 2016 Aug 18. pii: clinchem.2015.253740. [Epub ahead of print].

Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma.
Schneiderova P et al. Oncotarget. 2016 Aug 12. doi: 10.18632/oncotarget.11242. [Epub ahead of print].

Increased Hepatic Iron Content Predicts Poor Survival in Patients With Iron Overload Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation.
Sivgin S et al. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S10-8. doi: 10.1016/j.clml.2016.02.005.

N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma.
Milani P et al. Am J Hematol. 2016 Aug 10. doi: 10.1002/ajh.24532. [Epub ahead of print].

Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen.
Jung SH et al. BMC Cancer. 2016 Aug 8;16:613. doi: 10.1186/s12885-016-2645-y.

The Predictive Role of the Neutrophil/Lymphocyte Ratio in Survival with Multiple Myeloma: A Single Center Experience.
Onec B et al. J Clin Lab Anal. 2016 Aug 8. doi: 10.1002/jcla.22032. [Epub ahead of print].

Massive central nervous system infiltration by CD56-positive plasma cells in multiple myeloma.
Lopes AC et al. Cytopathology. 2016 Aug 3. doi: 10.1111/cyt.12365. [Epub ahead of print].

Evaluating acetate metabolism for imaging and targeting in multiple myeloma.
Fontana F et al. Clin Cancer Res. 2016 Aug 2. pii: clincanres.2134.2015. [Epub ahead of print].

Serum Free Light Chain Assay and κ/λ Ratio Performance in Patients Without Monoclonal Gammopathies: High False-Positive Rate.
Singh G et al. Am J Clin Pathol. 2016 Aug;146(2):207-14. doi: 10.1093/ajcp/aqw099.

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.
Jethava Y et al. Blood Cancer J. 2016 Jul 29;6(7):e453. doi: 10.1038/bcj.2016.64.